PolyNovo share price soars 12% amid 'exciting times ahead'

Shares in the medical devices developer are up on good news from the company today.

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • PolyNovo has come out of its trading halt this afternoon 
  • The company has announced the first sales of a new product and boosted revenue in March 
  • The PolyNovo share price has vastly outperformed the ASX All Ords over the past 12 months 

The PolyNovo Ltd (ASX: PNV) share price has galloped out of its trading halt after the company announced its first sales of a new product and bumper revenue in March.

The PolyNovo share price hit a high of $1.82 shortly after trading resumed, up 11.65% on yesterday's closing price.

The ASX healthcare share has since pulled back a little to $1.76, up 7.98%.

Let's take a look at the details.

What's the news pushing the PolyNovo share price higher?

The medical device company's new product is an advanced wound care treatment called NovoSorb MTX.

It received approval from the United States Food and Drug Administration in September 2022.

PolyNovo announced it has sold the new treatment to two hospitals in the US. It said its first sales had "occurred faster than expected".

PolyNovo is an Australian company that designs, develops, and manufactures dermal regeneration
solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology.

It created NovoSorb MTX in response to feedback from clinicians, who told them some wounds don't require the sealing membrane contained in the primary product, NovoSorb BTM.

NovoSorb MTX simplifies wound management and has wider applications for common wound-healing problems.

PolyNovo now expects to sell both products to clinicians in the future.

The company says NovoSorb MTX expands its addressable US market by an estimated AU$500 million.

NovoSorb MTX is indicated for use in partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic and vascular ulcers, diabetic ulcers, and surgical and trauma wounds.

What did management say?

PolyNovo Chair David Williams said:

I often refer to PolyNovo as taking baby steps on an upward evolving sales trajectory responding to the untapped indications that surgeons have found for it and an evolving response to large untapped markets such as India, Japan, and China.

NovoSorb MTX gives us the opportunity to take a big step forward.

What else did PolyNovo announce today?

PolyNovo also announced revenue numbers for the month of March.

The company revealed unaudited revenue of $6.4 million in March. This is up 48.2% on the March 2022 revenue of $4.3 million.

During the month, the company achieved record sales of NovoSorb BTM worth $5.45 million.

Sales revenue (unaudited) for the nine months to 31 March 2023 now totals $41.1 million. This is a 49.8% boost compared to the prior corresponding period.

Since the start of the year, the company has gained 26 new hospital customers in the US, three in Canada, and three in Hong Kong.

In India, PolyNovo has trained its sales staff and deployed them to the regions, with the first sale already recorded.

Williams said:

Sales will be lumpy for some time, but the trajectory is clear, and we see exciting times ahead in multiple jurisdictions.

We believe the quick first sales we have had in India, Canada and Hong Kong are a good indicator of early adoption by surgeons.

PolyNovo share price snapshot

The PolyNovo share price is up 87% over the past year.

It has vastly outperformed the S&P/ASX All Ordinaries Index (ASX: XAO), which is down 1.3% over the same period.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »